Health / WORLD

EMA safety committee assessed 85 medicine reports in October

PRAC’s monthly figures list nine safety signals, 49 risk-management plans and 16 post-authorisation studies.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) published October figures after its 28 September–1 October meeting. Its monthly summary lists 85 single assessments of periodic safety update reports, 49 risk-management plans for centrally authorised medicines and 16 post-authorisation safety studies.

The committee reported nine safety signals: five were started and four were ongoing or concluded. EMA said the committee did not start or conclude any referral procedure at the meeting. These counts do not establish that a medicine caused harm or that a new restriction was imposed.

The agency says the monthly figures are based on the draft agenda. It defines a safety signal as information that may suggest a medicine-event association requiring further investigation; a signal alone is not proof of causation.

Data

Key figures

PRAC October statistics

Monthly assessment counts based on the draft agenda.

Safety signals
9 count
2026-10 · Observed
PSUR single assessments
85 count
2026-10 · Observed
Risk-management plans for centrally authorised medicines
49 count
2026-10 · Observed
Post-authorisation safety studies
16 count
2026-10 · Observed
Referrals started, ongoing or concluded
0 count
2026-10 · Observed
Methodology

A safety signal is not proof of causation; all counts are based on the draft agenda.

Updated:

Structured coverage

Subjects and places

Subject proposals

Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

AIFA places three new medicines in class pending reimbursement assessment

Italy’s medicines agency published 1 October determinations for Itvisma, Jascayd and Liraglutide Stada on 17 October. All three were placed in class C(nn), for medicines not yet assessed for reimbursement.

Agenzia Italiana del Farmaco (AIFA)1 min read Data included
Health

WHO conducts preliminary assessment of Ethiopia medicine-quality lab

WHO experts conducted a technical preliminary assessment of the Ethiopian Food and Drug Authority’s medicines quality-control laboratory in preparation for possible WHO listing. The visit took place from 22 to 24 September.

WHO Regional Office for Africa1 min read Data included